MarketCapExport financials
Amicus Therapeutics (FOLD)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Amicus Therapeutics Financial Ratios 2025-2002 | FOLD
Brief overview of Amicus Therapeutics's valuation multiples
Ratios are assessed across five available annual reports in the 2021–2025 interval.
The valuation comparison uses P/S 6.98x (median 8.36x), P/B 16.14x (median 16.14x). On average, multiples differ from their five-year medians by only -8.3%. Valuation is near its familiar historical range.
Returns on assets and capital are represented by ROE -9.9%, ROA -2.9%, ROCE 12%. Current return ratios are negative, materially weakening the fundamental profile.
Price, earnings and growth produce a PEG of 3.71x. A high value reduces the cushion if growth slows.
The cash conversion cycle lengthened from 100.8 days to 828.1 days, or 727.3 days. More cash is tied up in operations.
Overall assessment
Amicus Therapeutics's valuation and business quality look relatively balanced, with no pronounced distortion in either direction.
Annual Financial Ratios Amicus Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -163.2 | -51.9 | -25.5 | -16.7 | -10.2 | -17.7 | -6.1 | -6.2 | -8.7 | -6.1 | -5.0 | -8.3 | -2.4 | -3.4 | -5.1 | - | - | - | - | - | - | - | - | - | |
P/S |
7.0 | 5.5 | 9.7 | 12.0 | 8.4 | 18.8 | 12.0 | 23.8 | 66.6 | 246.0 | - | 467.7 | 399.8 | 9.1 | 10.5 | - | - | - | - | - | - | - | - | - |
EPS |
-0.1 | -0.2 | -0.5 | -0.8 | -0.9 | -1.1 | -1.5 | -1.9 | -1.9 | -1.5 | -1.2 | -0.9 | -1.2 | -1.1 | -1.3 | -2.0 | -0.3 | - | - | - | - | - | - | - |
EV (Enterprise Value) |
4.89 B | 3.29 B | 4.23 B | 4.4 B | 2.91 B | 5.33 B | 2.41 B | 2.54 B | 2.68 B | 1.03 B | 1.16 B | 636 M | 183 M | 174 M | 240 M | -29.6 M | -19.3 M | -28.1 M | - | - | - | - | - | - |
EBITDA per Share |
0.13 | 0.11 | -0.23 | -0.72 | -0.74 | -0.92 | -1.23 | -1.73 | -1.35 | -0.791 | -1.13 | -0.902 | -1.18 | -1.12 | -1.43 | -1.94 | - | - | - | - | - | - | - | - |
EV/EBITDA |
121.4 | 98.4 | -61.1 | -21.3 | -14.0 | -21.8 | -7.4 | -7.5 | -12.4 | -6.8 | -5.1 | -8.4 | -1.9 | -2.6 | -4.1 | 0.5 | 3.7 | - | - | - | - | - | - | - |
PEG |
3.71 | 0.99 | 0.88 | 1.72 | -2.03 | -6.0 | -0.29 | 3.83 | 0.36 | -0.23 | 0.17 | -0.42 | 0.29 | -0.21 | -0.14 | - | - | - | - | - | - | - | - | - |
P/B |
16.1 | 15.0 | 24.1 | 32.1 | 8.3 | 17.1 | 4.6 | 6.3 | 7.0 | - | 1.9 | 4.7 | 3.2 | 2.4 | 7.6 | - | - | - | - | - | - | - | - | - |
P/CF |
133.5 | -85.9 | -55.9 | -23.7 | -12.6 | -21.0 | -8.1 | -7.1 | -11.2 | -7.8 | -6.3 | -11.0 | -3.1 | -4.4 | -4.4 | - | - | - | - | - | - | - | - | - |
ROE % |
-9.89 | -28.91 | -94.64 | -192.26 | -81.49 | -96.67 | -74.80 | -101.77 | -80.49 | - | -37.98 | -56.41 | -130.34 | -70.48 | -150.08 | -84.60 | -9.14 | -55.40 | -39.85 | 59.79 | 55.74 | 54.07 | 87.79 | 142.11 |
ROA % |
-2.85 | -7.15 | -19.49 | -32.67 | -27.67 | -31.23 | -41.92 | -44.18 | -45.29 | - | -14.54 | -32.83 | -46.75 | -44.31 | -63.63 | -48.81 | - | - | - | - | - | - | - | - |
ROCE % |
11.96 | 12.82 | -48.20 | -172.39 | -67.16 | -86.25 | -41.69 | -46.24 | -37.86 | - | -15.10 | -36.18 | -53.11 | -52.49 | -100.69 | -85.99 | -10.23 | - | - | - | - | - | - | - |
Current Ratio |
1.4 | 1.3 | 1.3 | 1.2 | 1.5 | 1.5 | 4.0 | 6.4 | 5.6 | - | 2.9 | 7.7 | 8.4 | 11.3 | 3.5 | - | - | - | - | - | - | - | - | - |
DSO |
62.3 | 65.2 | 70.3 | 65.9 | 59.5 | 56.1 | 66.7 | 87.9 | 93.5 | - | - | - | 763.2 | 63.9 | 85.9 | - | - | - | - | - | - | - | - | - |
DIO |
869.8 | 615.2 | 408.3 | 239.4 | 245.6 | 197.5 | 233.3 | 212.6 | 270.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
104.0 | 96.7 | 149.3 | 174.6 | 204.3 | 228.0 | 361.0 | 167.4 | 460.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
932.1 | 680.4 | 478.6 | 305.3 | 305.1 | 253.6 | 300.0 | 300.5 | 364.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
828.1 | 583.7 | 329.3 | 130.7 | 100.8 | 25.6 | -61.0 | 133.1 | -96.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Amicus Therapeutics
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.28 | -0.02 | -0.05 | -0.16 | - | -0.02 | -0.05 | -0.16 | - | -0.07 | -0.15 | -0.18 | - | -0.12 | -0.21 | -0.3 | - | -0.19 | -0.19 | -0.25 | -0.27 | -0.25 | -0.2 | -0.35 | -0.35 | -0.24 | -0.36 | -0.56 | -0.43 | -0.84 | -0.33 | -0.28 | -0.42 | -0.69 | -0.34 | -0.39 | -0.41 | -0.33 | -0.4 | -0.35 | -0.34 | -0.32 | -0.27 | -0.25 | -0.24 | -0.22 | -0.22 | -0.25 | -0.22 | -0.29 | -0.31 | -0.35 | -0.2 | -0.34 | -0.2 | -0.35 | -0.25 | -0.28 | -0.37 | -0.39 |
EBITDA per Share |
10.3 | 0.08 | 0.06 | -0.08 | - | 0.08 | 0.06 | -0.08 | - | -0.05 | -0.06 | -0.12 | - | -0.11 | -0.2 | -0.26 | - | -0.15 | -0.14 | -0.19 | - | -0.19 | -0.19 | -0.3 | - | -0.22 | -0.32 | -0.38 | - | -0.82 | -0.24 | -0.31 | - | -1.71 | -0.32 | -0.36 | - | -0.31 | -0.37 | -0.34 | - | -0.32 | -0.27 | -0.25 | - | -0.21 | -0.21 | -0.24 | - | -0.3 | -0.31 | -0.34 | - | -0.34 | -0.19 | -0.27 | - | -0.36 | -0.41 | -0.28 |
ROE % |
-94.64 | -47.99 | -55.64 | -82.88 | -52.66 | -68.85 | -103.83 | -143.59 | -106.54 | -131.65 | -151.30 | -148.29 | -96.68 | -110.03 | -108.87 | -99.20 | -63.47 | -88.40 | -97.40 | -91.79 | -96.67 | -90.57 | -81.20 | -80.61 | -74.80 | -78.74 | -112.18 | -112.47 | -101.77 | -98.62 | -83.85 | -79.46 | -80.49 | -77.16 | -58.47 | -59.00 | -55.54 | -51.59 | -49.51 | -43.13 | -37.98 | -43.02 | -46.19 | -50.35 | -56.41 | -65.79 | -83.65 | -105.23 | -130.34 | -118.06 | -109.71 | -89.66 | -70.48 | -85.28 | -94.73 | -123.95 | -150.08 | -32.98 | -42.72 | -45.11 |
ROA % |
-19.31 | -9.88 | -11.12 | -11.94 | -5.77 | -11.70 | -18.40 | -16.30 | -16.30 | -20.68 | -28.17 | -27.51 | -19.95 | -26.46 | -22.08 | -30.18 | -19.87 | -27.93 | -29.89 | -29.30 | -31.23 | -33.73 | -33.78 | -37.80 | -41.92 | -41.25 | -54.13 | -52.01 | -44.18 | -45.33 | -42.99 | -42.84 | -45.29 | -39.91 | -26.60 | -23.85 | -19.29 | -18.36 | -18.02 | -16.08 | -14.54 | -19.93 | -23.93 | -27.91 | -32.83 | -32.31 | -35.58 | -40.66 | -46.75 | -46.25 | -49.61 | -46.07 | -44.31 | -47.63 | -46.81 | -56.44 | -63.63 | -13.98 | -18.11 | -19.13 |
ROCE % |
-48.20 | 17.67 | 15.44 | -15.11 | 2.20 | -10.58 | -39.60 | -87.58 | -66.37 | -91.90 | -114.07 | -128.74 | -92.05 | -103.31 | -95.94 | -82.13 | -50.56 | -68.98 | -75.65 | -84.76 | -63.61 | -75.64 | -73.26 | -72.39 | -45.13 | -90.68 | -92.33 | -92.68 | -75.62 | -153.62 | -121.41 | -122.47 | -106.08 | -118.56 | -54.04 | -52.64 | -37.90 | -48.83 | -44.10 | -37.54 | -25.60 | -39.36 | -40.10 | -45.14 | -38.23 | -71.31 | -92.53 | -118.56 | -105.77 | -130.21 | -110.63 | -91.17 | -53.46 | -97.85 | -123.17 | -143.45 | -127.93 | -44.38 | -49.76 | -33.79 |
Current Ratio |
1.3 | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | 1.2 | - | 1.3 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | - | 1.4 | 1.5 | 1.6 | 1.4 | 1.4 | 1.5 | 1.5 | 1.5 | 1.5 | 2.3 | 2.3 | 2.3 | 2.3 | 1.8 | 1.8 | 1.8 | 1.8 | 2.3 | 2.3 | 2.3 | 2.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
444.2 | 65.2 | 72.8 | 78.0 | - | 59.1 | 30.7 | 36.2 | - | 60.4 | 63.7 | 71.1 | - | 29.2 | 29.6 | 60.9 | - | 57.7 | 55.5 | 63.1 | 60.7 | 63.5 | 68.7 | 60.5 | 54.9 | 62.3 | 68.8 | 74.0 | 61.4 | 97.3 | 94.0 | 85.9 | - | 79.4 | 120.7 | 117.8 | - | - | - | - | - | - | - | - | - | 119.6 | 49.3 | 112.2 | - | 2533.9 | - | - | - | 16.0 | 27.7 | 48.5 | - | 79.4 | 113.9 | - |
DIO |
-13878.2 | 816.2 | 962.5 | 600.2 | - | 675.7 | 329.5 | 200.8 | - | 496.9 | 392.4 | 334.0 | - | 45.1 | 135.4 | 307.8 | - | 180.1 | 233.5 | 267.6 | - | 212.5 | 267.3 | 233.9 | - | 229.0 | 238.7 | 252.4 | - | 177.6 | 244.2 | 227.0 | - | 235.7 | 397.6 | 473.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
-1512.7 | 89.0 | 104.9 | 94.4 | - | 156.5 | 129.9 | 50.9 | - | 168.2 | 192.7 | 265.4 | - | 40.9 | 127.5 | 267.3 | - | 149.2 | 162.6 | 231.5 | - | 185.4 | 233.2 | 270.1 | - | 354.2 | 369.3 | 318.7 | - | - | - | 137.3 | - | - | - | 759.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | 839.3 | 918.6 | 1048.7 | - | 734.8 | - | - | - | 557.3 | 456.1 | 405.1 | - | 74.3 | 165.0 | 368.7 | - | 237.8 | 289.0 | 330.7 | 60.7 | 275.9 | 336.0 | 294.4 | 54.9 | 291.2 | 307.6 | 326.4 | 61.4 | 274.9 | 338.3 | 312.9 | - | 315.1 | 518.2 | 591.1 | - | - | - | - | - | - | - | - | - | 119.6 | 49.3 | 112.2 | - | 2533.9 | - | - | - | 16.0 | 27.7 | 48.5 | - | 79.4 | 113.9 | - |
Cash Conversion Cycle |
- | 762.0 | 833.7 | 941.9 | - | 578.3 | - | - | - | 389.1 | 263.4 | 139.7 | - | 33.4 | 37.5 | 101.3 | - | 88.6 | 126.3 | 99.3 | 60.7 | 90.6 | 102.8 | 24.3 | 54.9 | -63.0 | -61.8 | 7.7 | 61.4 | 274.9 | 338.3 | 175.7 | - | 315.1 | 518.2 | -168.6 | - | - | - | - | - | - | - | - | - | 119.6 | 49.3 | 112.2 | - | 2533.9 | - | - | - | 16.0 | 27.7 | 48.5 | - | 79.4 | 113.9 | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Amicus Therapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Mereo BioPharma Group plc
MREO
|
$ 0.28 | -7.49 % | $ 223 M |  Britain |
 |
Maravai LifeSciences Holdings
MRVI
|
$ 6.94 | -10.1 % | $ 1 B |  USA |
 |
Lexicon Pharmaceuticals
LXRX
|
$ 1.61 | 8.78 % | $ 585 M | USA |
 |
Moleculin Biotech
MBRX
|
$ 8.72 | 3.07 % | $ 10.3 M | USA |
 |
Nurix Therapeutics
NRIX
|
$ 14.83 | -7.02 % | $ 1.29 B | USA |
 |
Nkarta
NKTX
|
$ 1.59 | -8.38 % | $ 118 M | USA |
 |
MacroGenics
MGNX
|
$ 2.24 | -3.25 % | $ 141 M | USA |
 |
ImmuCell Corporation
ICCC
|
$ 9.88 | -4.77 % | $ 89.2 M | USA |
 |
Nuvation Bio
NUVB
|
$ 4.19 | -11.42 % | $ 1.43 B | USA |
 |
Novo Nordisk A/S
NVO
|
$ 40.27 | -4.52 % | $ 179 B |  Danmark |
 |
Marker Therapeutics
MRKR
|
$ 0.9 | -11.24 % | $ 13.8 M | USA |
 |
NextCure
NXTC
|
$ 5.16 | -12.39 % | $ 14.7 M | USA |
 |
Olema Pharmaceuticals
OLMA
|
$ 6.89 | -8.62 % | $ 599 M | USA |
 |
Kymera Therapeutics
KYMR
|
$ 124.88 | -8.34 % | $ 10.6 B | USA |
 |
Oragenics
OGEN
|
$ 0.34 | -9.47 % | $ 733 K | USA |
 |
Ovid Therapeutics
OVID
|
$ 2.59 | -5.66 % | $ 337 M | USA |
 |
Passage Bio
PASG
|
$ 3.44 | -2.14 % | $ 11 M | USA |
 |
Vaxcyte
PCVX
|
$ 62.47 | -4.89 % | $ 8.5 B | USA |
 |
Precigen
PGEN
|
$ 4.2 | -16.94 % | $ 1.31 B | USA |
 |
Phio Pharmaceuticals Corp.
PHIO
|
$ 0.81 | -7.25 % | $ 4.85 M | USA |
 |
Praxis Precision Medicines
PRAX
|
$ 262.42 | -7.85 % | $ 5.91 B | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
$ 3.55 | -12.99 % | $ 273 M | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
$ 1.34 | -5.32 % | $ 141 M |  Niderland |
 |
Ocular Therapeutix
OCUL
|
$ 6.48 | -9.31 % | $ 1.21 B | USA |
 |
PolyPid Ltd.
PYPD
|
$ 5.8 | -0.34 % | $ 94.8 M |  Israel |
 |
Summit Therapeutics
SMMT
|
$ 14.17 | -12.37 % | $ 10.6 B | Britain |
 |
Outlook Therapeutics
OTLK
|
$ 0.44 | -4.63 % | $ 15.3 M | USA |
 |
uniQure N.V.
QURE
|
$ 20.96 | -9.01 % | $ 1.21 B | Niderland |
 |
Ultragenyx Pharmaceutical
RARE
|
$ 15.55 | -9.38 % | $ 1.53 B | USA |
 |
Rafael Holdings
RFL
|
$ 1.06 | -4.5 % | $ 54.5 M | USA |
 |
REGENXBIO
RGNX
|
$ 7.37 | -4.47 % | $ 380 M | USA |
 |
Sanofi
SNY
|
$ 46.87 | -1.26 % | $ 57.2 B |  France |
 |
Rigel Pharmaceuticals
RIGL
|
$ 45.56 | -11.17 % | $ 819 M | USA |
 |
Celsion Corporation
CLSN
|
- | -6.63 % | $ 13.9 M | USA |
 |
Генетико
GECO
|
- | - | - |  Russia |
 |
I-Mab
IMAB
|
- | - | $ 866 M |  China |
 |
Tenax Therapeutics
TENX
|
$ 1.65 | -8.84 % | $ 64.7 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | France |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | France |
 |
Scholar Rock Holding Corporation
SRRK
|
$ 45.27 | -1.78 % | $ 5.19 B | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M |  Germany |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
- | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
- | - | $ 4.9 B | Britain |
|
Rezolute
RZLT
|
$ 3.65 | -7.95 % | $ 379 M | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Britain |
 |
Tiziana Life Sciences PLC
TLSA
|
$ 0.62 | -2.71 % | $ 66.1 M | Britain |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Germany |
 |
Affimed N.V.
AFMD
|
- | -34.95 % | $ 21.5 M | Germany |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
$ 1.72 | 1.04 % | $ 1.16 B | Israel |